Purpose To determine the utility of cardiac magnetic resonance (MR) T1 mapping for
quantification of diffuse myocardial fibrosis compared with the standard of endomyocardial …

Hypertrophic cardiomyopathy (HCM) is characterized by substantial genetic and phenotypic
heterogeneity, leading to considerable diversity in clinical course including the most …

Background—Cardiac involvement predicts outcome in systemic AL amyloidosis and
influences therapeutic options. Current methods of cardiac assessment do not quantify …

Background Circulating microRNAs may represent novel markers for cardiovascular
diseases. We evaluated whether circulating miRNAs served as potential biomarkers for …

Systemic amyloidosis is a relatively rare multisystem disease caused by the deposition of
misfolded protein in various tissues and organs. It may present to almost any specialty, and …

Background Quantitative T1-mapping is rapidly becoming a clinical tool in cardiovascular
magnetic resonance (CMR) to objectively distinguish normal from diseased myocardium …

Background: Optimal patient characterization in heart failure with preserved ejection fraction
(HFpEF) is essential to tailor successful treatment strategies. Cardiac magnetic resonance …

Abstract Background Myocardial T 1 and T 2 mapping using cardiovascular magnetic
resonance (CMR) are promising to improve tissue characterization and early disease …

Aim The aim of this study was to determine the value of extracellular volume fraction (ECV)
for the non-invasive assessment of diffuse myocardial fibrosis (MF) in different stages of …

Background: Left ventricular (LV) hypertrophy, a key process in human cardiac disease,
results from cellular (hypertrophy) and extracellular matrix expansion (interstitial fibrosis) …